Skip to main navigation

Technology
Pipeline
About Us
Investors & Media
Careers & Culture

Clinical Trials
News Center
Contact Us

Investors & Media

Quarterly Results

BACK TO OVERVIEW
Quarterly Results
SEC Filings

Show all

2023

Q3

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023
Form 10-Q

Q2

Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023
Form 10-Q

Q1

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023
Form 10-Q

2022

Q4

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022
Form 10-K

Q3

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022
Form 10-Q

Q2

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022
Form 10-Q

Q1

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022
Form 10-Q

2021

Q4

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021
Form 10-K

Q3

Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021
Form 10-Q

Q2

Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021
Form 10-Q

Q1

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021
Form 10-Q

2020

Q4

Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020
Form 10-K

Q3

Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020
Form 10-Q

Q2

Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020
Form 10-Q

Email Alerts
Investor Contact
Search
Print Page

Social Links

linkedin
twitter
youtube
accessibility

Footer Privacy Policy link

Contact
Privacy Policy
Expanded Access Policy
Accessibility Statement

© 2023 Poseida Therapeutics, Inc. | All rights reserved.